Russell Investments Group, Ltd. Nurix Therapeutics, Inc. Transaction History

Russell Investments Group, Ltd.

$66.8 Billion
Q3 2024

A detailed history of Russell Investments Group, Ltd. transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 728 shares of NRIX stock, worth $19,554. This represents 0.0% of its overall portfolio holdings.

Number of Shares

728

Previous 3,473 79.04%

Holding current value

$19,554

Previous $72,000 77.78%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$18.93 - $25.69 $51,962 - $70,519	-2,745 Reduced 79.04%	728 $16,000
Q2 2024 Aug 08, 2024	SELL	$12.02 - $21.3 $601,829 - $1.07 Million	-50,069 Reduced 93.51%	3,473 $72,000
Q1 2024 May 08, 2024	BUY	$7.77 - $15.66 $179,051 - $360,869	23,044 Added 75.56%	53,542 $787,000
Q4 2023 Feb 05, 2024	BUY	$4.25 - $10.71 $63 - $160	15 Added 0.05%	30,498 $314,000
Q3 2023 Nov 13, 2023	SELL	$7.86 - $10.08 $39,873 - $51,135	-5,073 Reduced 14.27%	30,483 $239,000
Q2 2023 Aug 10, 2023	SELL	$8.7 - $13.28 $9,744 - $14,873	-1,120 Reduced 3.05%	35,556 $355,000
Q1 2023 May 09, 2023	BUY	$8.56 - $13.26 $107,744 - $166,903	12,587 Added 52.25%	36,676 $325,000
Q4 2022 Feb 08, 2023	BUY	$9.86 - $14.59 $228,850 - $338,633	23,210 Added 2640.5%	24,089 $264,000
Q3 2022 Nov 04, 2022	BUY	$12.33 - $19.81 $10,838 - $17,412	879 New	879 $11,000
Q3 2021 Nov 08, 2021	SELL	$22.71 - $36.69 $130,559 - $210,930	-5,749 Closed	0 $0
Q1 2021 May 10, 2021	BUY	$26.98 - $50.17 $155,108 - $288,427	5,749 New	5,749 $178,000

Others Institutions Holding NRIX

# of Institutions

180

Shares Held

68.1M

Call Options Held

78K

Put Options Held

53.8K

View Full List

About Nurix Therapeutics, Inc.

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $1.27B
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

More about NRIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.

Account

Russell Investments Group, Ltd. Nurix Therapeutics, Inc. Transaction History